The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
Contemp Clin Trials Commun
; 22: 100780, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-34013094
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Guideline
Language:
En
Journal:
Contemp Clin Trials Commun
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: